Showing 1,521 - 1,540 results of 1,859 for search '"Immunotherapy"', query time: 0.07s Refine Results
  1. 1521

    Gastric Cancer Mesenchymal Stem Cells Inhibit NK Cell Function through mTOR Signalling to Promote Tumour Growth by Shuwei Guo, Chao Huang, Fengfeng Han, Bin Chen, Ying Ding, Yuanyuan Zhao, Zhihong Chen, Shaodi Wen, Mei Wang, Bo Shen, Wei Zhu

    Published 2021-01-01
    “…The study results revealed that GCMSCs contributed to dysfunctional NK cells involved at least partially in the inhibition of mTOR signalling, suggesting potential directions for NK cell-based cancer immunotherapy.…”
    Get full text
    Article
  2. 1522

    DGAT1 Expression Promotes Ovarian Cancer Progression and Is Associated with Poor Prognosis by Leilei Xia, Ye Wang, Shengyun Cai, Mingjuan Xu

    Published 2021-01-01
    “…Owing to its insidious onset, rapid development, and poor prognosis, ovarian cancer is the fifth most common cause of death in women. Although immunotherapy-related drugs, such as Olaparib, can alleviate ovarian cancer progression, there are no remarkable breakthroughs for its effective treatment. …”
    Get full text
    Article
  3. 1523

    Disulfidptosis-related immune patterns predict prognosis and characterize the tumor microenvironment in oral squamous cell carcinoma by Xuechen Wu, Boxin Liu, Shi-Zhou Deng, Tengteng Xiong, Lin Dai, Bo Cheng

    Published 2025-02-01
    “…With this model, we can more accurately predict the prognosis of patients with OSCC, as well as assess the potential effects of their TME and immunotherapy.…”
    Get full text
    Article
  4. 1524

    SLC2A5 Correlated with Immune Infiltration: A Candidate Diagnostic and Prognostic Biomarker for Lung Adenocarcinoma by Lianxiang Luo, Jiating Su, Yushi Zheng, Fangfang Huang, Riming Huang, Hui Luo

    Published 2021-01-01
    “…Great advances in new immunotherapy strategies have shown encouraging results in lung cancer patients. …”
    Get full text
    Article
  5. 1525

    Tumor-derived colorectal cancer organoids induce a unique Treg cell population by directing CD4+ T cell differentiation by Sonia Aristin Revilla, Cynthia L. Frederiks, Stefan Prekovic, Enric Mocholi, Onno Kranenburg, Paul J. Coffer

    Published 2025-02-01
    “…Summary: In colorectal cancer (CRC), increased numbers of tumor-infiltrating CD4+ regulatory T (Treg) cells correlate with tumor development, immunotherapy failure, and poor prognosis. To assess how CRC tumors directly modulate Treg cell differentiation, we developed an in vitro co-culture system using CD4+ T cells from Foxp3eGFP mice and CRC tumor-derived organoids. …”
    Get full text
    Article
  6. 1526

    Multicellular model of neuroblastoma proposes unconventional therapy based on multiple roles of p53. by Kenneth Y Wertheim, Robert Chisholm, Paul Richmond, Dawn Walker

    Published 2024-12-01
    “…Over half of all high-risk cases are expected to succumb to the disease even after chemotherapy, surgery, and immunotherapy. Although the importance of MYCN amplification in this disease is indisputable, the mechanistic details remain enigmatic. …”
    Get full text
    Article
  7. 1527

    2’-Fucosyllactose alleviate immune checkpoint blockade-associated colitis by reshaping gut microbiota and activating AHR pathway by Shikai Yan, Leilei Yu, Fengwei Tian, Jianxin Zhao, Wei Chen, Qixiao Zhai

    Published 2024-09-01
    “…Immune checkpoint blockade (ICB) therapeutics are highly effective in cancer immunotherapy, but gastrointestinal toxicity limited the application. …”
    Get full text
    Article
  8. 1528

    A generative deep neural network for pan-digestive tract cancer survival analysis by Lekai Xu, Tianjun Lan, Yiqian Huang, Liansheng Wang, Junqi Lin, Xinpeng Song, Hui Tang, Haotian Cao, Hua Chai

    Published 2025-01-01
    “…The following drug analysis suggested Dasatinib and YM155 as potential therapeutic agents for improving the prognosis of patients in pan-DTC immunotherapy, thereby contributing to the enhancement of cancer patient survival. …”
    Get full text
    Article
  9. 1529

    Metastatic brain tumors: from development to cutting‐edge treatment by Guilong Tanzhu, Liu Chen, Jiaoyang Ning, Wenxiang Xue, Ce Wang, Gang Xiao, Jie Yang, Rongrong Zhou

    Published 2025-01-01
    “…For lung cancer, targeted therapy and immunotherapy have shown efficacy, while in breast cancer, monoclonal antibodies, tyrosine kinase inhibitors, and antibody–drug conjugates are effective in BM. …”
    Get full text
    Article
  10. 1530

    NEIL3 Mediates Lung Cancer Progression and Modulates PI3K/AKT/mTOR Signaling: A Potential Therapeutic Target by Hongbo Huang, Qingwang Hua

    Published 2022-01-01
    “…In general, NEIL3 mediates NSCLC progression and affects sensitivity to immunotherapy and chemotherapy; therefore, it is a potential molecular target for treatment.…”
    Get full text
    Article
  11. 1531

    Clinical, histopathological and parasitological follow-up of dogs naturally infected by Leishmania infantum before and after miltefosine treatment and associated therapies. by Amábilli de Souza Rosar, Carolina Leite Martins, Álvaro Menin, Carolina Reck, Edmundo Carlos Grisard, Glauber Wagner, Mário Steindel, Patricia Hermes Stoco, Patricia Flavia Quaresma

    Published 2025-01-01
    “…Three dogs were treated exclusively with miltefosine, while eighteen received combination therapy with miltefosine with other treatments such as allopurinol, domperidone and immunotherapy. Skin biopsies were obtained from the abdomen to assess inflammatory responses and to quantify parasite loads using qPCR. …”
    Get full text
    Article
  12. 1532

    Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States by Robert L. Coleman, Jamie Garside, Jean Hurteau, Joehl Nguyen, Monica Kobayashi

    Published 2023-10-01
    “…Of the patients who received at least 1 LOT, use of immunotherapy in the second-line setting was more common in the dMMR/MSI-H subgroup. …”
    Get full text
    Article
  13. 1533
  14. 1534
  15. 1535

    Radiomics and radiogenomics in intrahepatic cholangiocarcinoma by A. D. Smirnova, G. G. Karmazanovsky, E. V. Kondratyev, N.  A. Karelskaya, V. N. Galkin, A.  Yu. Popov, B. N. Gurmikov, D. V. Kalinin

    Published 2024-03-01
    “…Correlation of texture features with the expression of immunotherapy target genes KRAS/NRAS/BRAF as well as IDH1/2 mutation was shown. …”
    Get full text
    Article
  16. 1536

    Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab by Ziping Li, Fujing Zhang, Xianghong Jin, Junling Zhuang

    Published 2025-01-01
    “…Abstract Background Immunotherapy is a significant risk factor for severe COVID-19 in multiple myeloma (MM) patients. …”
    Get full text
    Article
  17. 1537

    Cancer-associated fibroblasts and their role in tumor progression by M. S. Ermakov, A. A. Nushtaeva, V. A. Richter, O. A. Koval

    Published 2022-03-01
    “…CAFs control tumor angiogenesis, cell motility, tumor immunogenic properties, and the development of resistance to chemo- and immunotherapy. As a result of metabolic adaptation of rapidly growing tumor tissue to the nutrients and oxygen deprivation, the main type of energy production in cells changes from oxidative phosphorylation to anaerobic glycolysis. …”
    Get full text
    Article
  18. 1538

    Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy by Shixue Chen, Lingling Li, Fan Zhang, Yu Wang, Yi Hu, Lei Zhao

    Published 2019-01-01
    “…Bispecific antibodies (BsAbs) are a sort of dual functional proteins with specific binding to two distinct targets, which have become a focus of interest in antibody engineering and drug development research and have a promising future for wide applications in cancer immunotherapy and autoimmune disease. The key of clinical application and commercial-scale manufacturing of BsAbs is the amenability to assembly and purification of desired heterodimers. …”
    Get full text
    Article
  19. 1539

    Glutamine and cancer: metabolism, immune microenvironment, and therapeutic targets by Ding Nan, Weiping Yao, Luanluan Huang, Ruiqi Liu, Xiaoyan Chen, Wenjie Xia, Hailong Sheng, Haibo Zhang, Xiaodong Liang, Yanwei Lu

    Published 2025-01-01
    “…With the encouraging results of cancer immunotherapy in recent years, more investigation into the impact of glutamine metabolism on immune cell function in the cancer microenvironment could lead to the discovery of new targets and therapeutic approaches. …”
    Get full text
    Article
  20. 1540

    DNA methylation of ACADS promotes immunogenic cell death in hepatocellular carcinoma by Ze Qian, Yifan Jiang, Yacong Wang, Yu Li, Lin Zhang, Xiaofeng Xu, Diyu Chen

    Published 2025-01-01
    “…We also discovered a correlation between ACADS and ICD, suggesting that ACADS is an essential target for immunotherapy in HCC. Graphical Abstract…”
    Get full text
    Article